Qualitative study of the feasibility of HPV vaccine delivery to young adolescent girls in Vietnam: Evidence from a government-implemented demonstration program

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Lamontagne, D Scott ^a   Nghi, Nguyen Quy ^b   Nga, Le Thi ^c   Janmohamed, Amynah ^d   Huyen, Dang Thi Thanh ^e   Hien, Nguyen Tran ^e   Tsu, Vivien Davis ^a  

^a PATH   (United States)

^b WORLD BANK   (United States)

^c HealthBridge E4 Building Trung Tu Diplomatic Compound   (Viet Nam)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

Author keywords

Feasibility; Health system; HPV vaccine; School based; Vaccine delivery; Vietnam

Indexed keywords

WART VIRUS VACCINE;

CHILD; FEASIBILITY STUDY; FEMALE; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMATION PROCESSING; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREVENTIVE HEALTH SERVICE; QUALITATIVE RESEARCH; SCHOOL HEALTH SERVICE; UNIVERSITY; VIET NAM;

ATTITUDE OF HEALTH PERSONNEL; CHILD; DELIVERY OF HEALTH CARE; FACULTY; FEASIBILITY STUDIES; FEMALE; FOCUS GROUPS; GOVERNMENT PROGRAMS; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; QUALITATIVE RESEARCH; SCHOOL HEALTH SERVICES; VIETNAM;

EID: 84903529086     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-556     Document Type: Article

References (37)

1. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The FUTURE II Study Group, N Engl J Med 2007 356 19 1915 1927 17494925
2. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group, Lancet 2009 374 9686 301 314 10.1016/S0140-6736(09)61248-4 19586656
3. LaMontagne DS, HPV vaccination in low-resource countries: current evidence and global update. Public Health workshop. 28th International Papillomavirus Conference, San Juan, Puerto Rico, December 1, 2012
4. Human papillomavirus vaccine introduction - the first five years. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM, Vaccine 2012 30 Suppl 5 139 F148 23199957
5. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Koulova A, Tsui J, Irwin K, Van DP, Biellik R, Aguado MT, Vaccine 2008 26 51 6529 6541 10.1016/j.vaccine.2008.08.067 18805453
6. Progress in HPV vaccine introduction in Latin America. Munoz N, HPV Today 2012 27 10 11
7. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F, Bull World Health Organ 2012 90 8 623 628 10.2471/BLT.11.097253 22893746
8. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H, Vaccine 2011 29 19 3610 3616 10.1016/j.vaccine.2011.02.064 21382486
9. Assessment of the first HPV vaccination campaign in two northern Italian health districts. Chadenier GM, Colzani E, Faccini M, Borriello CR, Bonazzi C, Vaccine 2011 29 26 4405 4408 10.1016/j.vaccine.2011.04.007 21501645
10. Inter-State variation in human papillomavirus vaccine coverage among adolescent girls in the 50 US states, 2007. Kramer MR, Dunlop AL, Matern Child Health J 2012 16 Suppl 1 102 S110 22453332
11. National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program. Brotherton JM, Leask J, Jackson C, McCaffery K, Trevena LJ, Sex Health 2010 7 3 291 298 10.1071/SH09135 20719217
12. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Widgren K, Simonsen J, Valentiner-Branth P, Molbak K, Vaccine 2011 29 52 9663 9667 10.1016/j.vaccine. 2011.10.021 22015392
13. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. Leval A, Herweijer E, Arnheim- Dahlström L, Walum H, Frans E, Sparén P, Simard JF, J Infect Dis 2012 206 6 860 866 10.1093/infdis/jis405 22815381
14. Fall in human papillomavirus prevalence following a national vaccination program. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM, J Infect Dis 2012 206 11 1645 1651 10.1093/infdis/jis590 23087430
15. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK, Lancet Infect Dis 2011 11 1 39 44 10.1016/S1473-3099(10)70225-5 21067976
16. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, McCann R, BMJ 2008 336 7652 1056 1058 10.1136/bmj.39541.534109.BE 18436917
17. 'It's a logistical nightmare!' Recommendations for optimising human papillomavirus school-based vaccination experience. Robbins SC, Bernard D, McCaffery K, Skinner SR, Sex Health 2010 7 3 271 278 10.1071/SH09140 20719214
18. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 12 2893 2917 10.1002/ijc.25516 21351269
19. Strategies to vaccinate against cancer of the cervix: Feasibility of a school-based HPV vaccination program in Peru. Penny M, Bartolini R, Mosqueira NR, LaMontagne DS, Mendoza MA, Ramos I, Winkler JL, Villafana J, Janmohamed A, Jumaan AO, Vaccine 2011 29 5022 5030 10.1016/j.vaccine.2011.04.078 21609748
20. Assessment of eight HPV vaccination programs implemented in lowest income countries. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J, BMC Public Health 2012 12 370 10.1186/1471-2458-12-370 22621342
21. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Bingham A, Drake JK, LaMontagne DS, Arch Pediatr Adolesc Med 2009 163 5 455 461 10.1001/archpediatrics.2009.50 19414692
22. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, Gandhi S, Vaccine 2009 27 44 6203 6209 10.1016/j.vaccine.2009.08.003 19698808
23. Assessing the environment for introduction of human papillomavirus vaccine in India. Jacob M, Mawar N, Menezes L, Kaipilyawar S, Gandhi S, Khan I, Patki M, Bingham A, LaMontagne DS, Bagul R, Katendra T, Karandikar N, Madge V, Chaudhry K, Paranjape R, Nayyar A, Open Vacc J 2010 3 96 107 10.2174/1875035401003010096
24. Human papillomavirus vaccine introduction in Vietnam: formative research findings. Nghi NQ, LaMontagne DS, Bingham A, Rafiq M, Mai LTP, Lien NT, Khanh NC, Hong DT, Huyen DT, Tho NT, Hien NT, Sex Health 2010 7 3 262 270 10.1071/SH09123 20719213
25. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, Paul P, Tang Y, Minh TH, Uttekar BP, Jumaan AO, Bull World Health Organ 2011 89 11 821 830B 10.2471/BLT.11.08986 22084528
26. Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. Cover JK, Nghi NQ, LaMontagne DS, Huyen DT, Hien NT, Nga LT, BMC Public Health 2012 12 629 10.1186/1471-2458-12-629 22877158
27. Incremental costs of strategies to deliver human papillomavirus vaccine to young adolescent girls in Peru, Uganda, and Viet Nam. Levin CE, Minh HV, Odaga J, Rout SS, Diep NTN, Menezes L, Araujo MA, LaMontagne DS, Bull World Health Organ 2013 in press
28. Team-based codebook development: structure, process, and agreement. MacQueen KM, McLellan-Lemal E, Barthalow K, Milstein B, Handbook for team-based qualitative research Lanham: Altamira, Guest G, MacQueen KM, 2008 119 136
29. Standards of qualitative research. Frankel RM, Doing qualitative research Newbury Park, Calif: Sage Publications, Crabtree BF, Miller WL, 1992 333 346
30. Initial lessons learned in HPV vaccination. Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BJ, Gynecol Oncol 2008 109 2 Suppl 4 S11 18482557
31. HPV vaccine use in the developing world. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F, Vaccine 2006 24 132 139
32. HPV & HPV vaccination: issues in developing countries. Bharadwaj M, Hussain S, Nasare V, Das BC, Indian J Med Res 2009 130 3 327 333 19901442
33. Human papillomavirus vaccination for control of cervical cancer: a challenge for developing countries. Bello FA, Enabor OO, Adewole IF, Afr J Reprod Health 2011 15 1 25 30
34. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, Pitcher H, Scully M, Watson M, Webby R, Commun Dis Intell 2008 32 4 457 461
35. HPV vaccine in Rwanda: different disease, same double standard. Binagwaho A, Wagner CM, Nutt CT, Lancet 2011 378 9807 1916 10.1016/S0140-6736(11)61837-0 22137840
36. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R, J Infect Dis 2012 206 5 678 686 10.1093/infdis/jis407 22711908
37. A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils, and religious leaders in northwest Tanzania. Remes P, Selestine V, Changalucha J, Ross DA, Wight D, de Sanjosé S, Kapiga S, Hayes RJ, Watson-Jones D, Vaccine 2012 30 36 5363 5367 10.1016/j.vaccine.2012.06.025 22732428